KYNBNasdaqPharmaceutical PreparationsFiscal year ends December 31
KYNTRA BIO, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$5.28+0.43 (+8.87%)
Close on Oct 19, 2026
- Market cap
- $21.37M
- P/E (TTM)
- 0.1
- Dividend yield
- –
KYNTRA BIO, INC. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug Product Revenue [Member] | $5.85M | $27.67M | $18.75M | $11.09M | $962.00K | $8.91M | -$36.32M | $64.78M | – | – | 90.8% | -78.9% |
| Other Revenue - Contract Manufacturing [Member] | $592.00K | $1.95M | $18.40M | $24.19M | $70.28M | $80.59M | $114.12M | $125.91M | $121.06M | $132.58M | 9.2% | -69.6% |
| License [Member] | – | $0 | $9.65M | $22.59M | $116.43M | $14.32M | $177.09M | $22.27M | $9.93M | $50.61M | – | – |
| Product [Member] | – | – | $100.95M | $82.87M | $47.64M | $72.50M | $1.70M | $0 | $0 | $0 | – | – |
| API Product [Member] | – | – | – | – | – | – | -$36.32M | $64.78M | – | – | – | – |
| Drug Product [Member] | – | – | – | – | – | – | $1.70M | $0 | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Europe [Member] | $5.64M | $6.27M | $9.55M | $33.82M | $131.24M | $17.95M | $145.64M | $112.92M | $110.86M | $151.74M | 87.6% | -10.0% |
| Japan | $797.00K | -$2.85M | $15.87M | $9.76M | $2.31M | $19.82M | -$23.17M | $100.00M | – | – | 12.4% | -127.9% |
| China | $0 | $91.00K | $8.43M | $84.63M | $55.64M | $73.36M | $20.97M | $0 | – | – | 0.0% | -100.0% |
| United States | $0 | $26.11M | $12.96M | $12.52M | $46.12M | $65.18M | $113.13M | – | – | – | 0.0% | -100.0% |
| All other [Member] | – | – | – | – | $0 | $0 | $2.00K | $40.00K | $24.00K | $130.00K | – | – |
From the segment and revenue-disaggregation notes of Kyntra Bio's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.